Dr. Larry Kaskel welcomes Dr. James Ehrlich, chief medical officer of Atherotech and clinical associate professor in the endocrinology division of the University of Colorado School of Medicine, who has developed advanced coronary risk assessment programs in four U.S. cities. Dr. Ehrlich will describe evidence suggesting that office-based risk assessment (Framingham) fails to identify high risk individuals. He will detail which patients need advanced lipid testing as well as discuss tools and emerging biomarkers that are of highest value.
Brought to you by:
